Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKP09
- Development stage
- Preclinical
- Lead developer
- ASKA Pharmaceutical
01
Overview
AKP09 is a nutraceutical product currently in development by Damor Farmaceutici through its Akademy Pharma division, specifically targeting dermatological conditions. As part of the company's AKP pipeline series, it is categorized as a supplement or natural biopharmaceutical project. While Damor Farmaceutici is recognized for its research into natural extracts, such as *Triticum vulgare* for wound healing, the specific active ingredients and molecular targets of AKP09 remain proprietary and have not been publicly disclosed in company literature. The product is being developed to address needs within the dermatology therapeutic area, though its precise mechanism of action is not yet specified.
Beyond the preview
Go deeper on AKP09.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKP09.